MeSH term
Frequency | Condition_Probility | Adolescent | 18 | 0.0 |
Child | 25 | 0.0 |
Child, Preschool | 7 | 0.0 |
Complement 7/*deficiency/genetics | 11 | 91.0 |
DNA Mutational Analysis | 2 | 0.0 |
Family Health | 2 | 0.0 |
Female | 66 | 0.0 |
Humans | 185 | 0.0 |
Infant | 3 | 0.0 |
Male | 65 | 0.0 |
Mutation | 7 | 0.0 |
Pedigree | 27 | 0.0 |
Antibodies, Monoclonal | 2 | 0.0 |
English Abstract | 10 | 0.0 |
Enzyme-Linked Immunosorbent Assay/methods | 2 | 0.0 |
Polymerase Chain Reaction | 12 | 0.0 |
Research Support, Non-U.S. Gov't | 101 | 0.0 |
Middle Aged | 21 | 0.0 |
Aged | 17 | 0.0 |
Aged, 80 and over | 10 | 0.0 |
Adult | 38 | 0.0 |
Complement/analysis | 2 | 1.0 |
Recurrence | 5 | 0.0 |
Amino Acid Sequence | 13 | 0.0 |
Animals | 35 | 0.0 |
Base Sequence | 19 | 0.0 |
Molecular Sequence Data | 24 | 0.0 |
Phylogeny | 2 | 0.0 |
RNA, Messenger/metabolism | 5 | 0.0 |
Chromosome Mapping | 12 | 0.0 |
Complement/*genetics | 6 | 10.0 |
Ethnic Groups/genetics | 3 | 1.0 |
Genes, Structural | 2 | 0.0 |
Mice | 9 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 45 | 0.0 |
Biomechanics | 2 | 1.0 |
Aging/*physiology | 2 | 0.0 |
Binding Sites | 6 | 0.0 |
Kinetics | 9 | 0.0 |
Protein Conformation | 4 | 0.0 |
Rats | 8 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Cells, Cultured | 11 | 0.0 |
Complement 7/*biosynthesis/genetics | 2 | 100.0 |
Cell Line | 10 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 4 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Complement Hemolytic Activity Assay | 4 | 8.0 |
Rabbits | 7 | 0.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
Complement Membrane Attack Complex/*metabolism | 2 | 9.0 |
Macromolecular Substances | 6 | 0.0 |
Peptide Fragments/chemistry | 2 | 1.0 |
Spectrum Analysis, Mass | 2 | 0.0 |
Autoimmune Diseases/*genetics | 2 | 4.0 |
Complement 6/*genetics | 9 | 64.0 |
Complement 7/*genetics | 14 | 93.0 |
Gene Frequency | 7 | 0.0 |
Genotype | 4 | 0.0 |
Haplotypes/genetics | 3 | 0.0 |
Linkage (Genetics) | 4 | 0.0 |
Point Mutation | 3 | 0.0 |
Polymorphism, Genetic | 12 | 0.0 |
Evoked Potentials, Somatosensory/*physiology | 2 | 7.0 |
Alleles | 12 | 0.0 |
Genetic Markers | 10 | 0.0 |
Haplotypes | 6 | 0.0 |
*Polymorphism, Genetic | 10 | 0.0 |
*Alleles | 3 | 0.0 |
Complement 7/*deficiency/*genetics | 7 | 100.0 |
Polymorphism, Genetic/*genetics | 5 | 0.0 |
Ecuador | 2 | 18.0 |
*Gene Frequency | 3 | 0.0 |
Phenotype | 15 | 0.0 |
Alzheimer Disease/*metabolism | 3 | 1.0 |
Immunohistochemistry | 5 | 0.0 |
Reference Values | 6 | 0.0 |
DNA/genetics | 4 | 0.0 |
Isoelectric Focusing | 6 | 1.0 |
Complement/*analysis | 10 | 5.0 |
Pregnancy | 5 | 0.0 |
Blotting, Southern | 3 | 0.0 |
Exons | 2 | 0.0 |
Ireland | 3 | 5.0 |
Meningococcal Infections/genetics/immunology | 2 | 100.0 |
Blotting, Western | 7 | 0.0 |
DNA Primers | 2 | 0.0 |
Complement Activation/physiology | 2 | 10.0 |
Neurons/*metabolism | 3 | 1.0 |
Tumor Cells, Cultured | 2 | 0.0 |
Transfection | 3 | 0.0 |
Complement Pathway, Classical/*physiology | 2 | 18.0 |
Complement/*metabolism | 11 | 6.0 |
*Haplotypes | 2 | 0.0 |
*Polymorphism, Restriction Fragment Length | 3 | 0.0 |
Biological Transport | 2 | 0.0 |
Complement 6/genetics | 4 | 44.0 |
Genome, Human | 3 | 0.0 |
Complement Activation | 5 | 1.0 |
Protein Binding | 3 | 0.0 |
Epidermis/*immunology | 2 | 16.0 |
Immunoglobulin G/analysis | 3 | 0.0 |
Homozygote | 4 | 0.0 |
Molecular Weight | 7 | 0.0 |
Restriction Mapping | 2 | 0.0 |
Complement 7/*biosynthesis | 2 | 100.0 |
Prospective Studies | 2 | 0.0 |
Blood Donors | 2 | 0.0 |
Chronic Disease | 2 | 0.0 |
*Plasmapheresis | 2 | 6.0 |
Comparative Study | 16 | 0.0 |
Escherichia coli | 2 | 0.0 |
Liver Neoplasms | 2 | 0.0 |
Mutagenesis, Site-Directed | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 2 | 0.0 |
Complement 7/deficiency/*genetics | 3 | 75.0 |
*Complement Activation | 4 | 1.0 |
Species Specificity | 3 | 0.0 |
Complement 6/*deficiency/*genetics | 2 | 40.0 |
Polymorphism, Restriction Fragment Length | 7 | 0.0 |
Complement/analysis/*physiology | 2 | 66.0 |
Heterozygote | 3 | 0.0 |
Complement 1/analysis | 3 | 6.0 |
Complement 2/analysis | 3 | 10.0 |
Complement 3/analysis | 4 | 1.0 |
Complement 4/analysis | 3 | 1.0 |
Blood Proteins/*genetics | 3 | 1.0 |
Complement Pathway, Classical/genetics | 2 | 28.0 |
Enzyme-Linked Immunosorbent Assay | 7 | 0.0 |
Complement/metabolism | 2 | 2.0 |
Immunoblotting | 6 | 0.0 |
Complement 7/*deficiency | 3 | 60.0 |
Complement 9/*metabolism | 2 | 5.0 |
In Vitro | 6 | 0.0 |
*Linkage (Genetics) | 7 | 0.0 |
Cross Reactions | 4 | 0.0 |
Immunoglobulin M/analysis | 2 | 0.0 |
Immunoglobulin Variable Region/immunology | 2 | 6.0 |
Complement Membrane Attack Complex/*deficiency/genetics | 2 | 100.0 |
*Complement 5 | 2 | 22.0 |
Dose-Response Relationship, Drug | 2 | 0.0 |
Guinea Pigs | 5 | 0.0 |
Sheep | 3 | 0.0 |
*Chromosome Mapping | 4 | 0.0 |
Complement 9/*genetics | 2 | 25.0 |
Blotting, Northern | 2 | 0.0 |
Properdin/metabolism | 2 | 13.0 |
Sequence Homology, Nucleic Acid | 2 | 0.0 |
Karyotyping | 4 | 0.0 |
Sex Chromosome Aberrations/*genetics | 2 | 3.0 |
Syndrome | 4 | 0.0 |
*X Chromosome | 9 | 0.0 |
Asian Continental Ancestry Group | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
Chromosome Deletion | 3 | 0.0 |
Chromosomes, Fungal | 2 | 3.0 |
Glycerol Kinase/*deficiency | 2 | 33.0 |
DNA | 2 | 0.0 |
*Genetic Markers | 2 | 0.0 |
Muscular Dystrophies/*genetics | 7 | 8.0 |
DNA Probes | 3 | 0.0 |
Histocompatibility Testing | 2 | 0.0 |
Autoimmune Diseases/immunology | 2 | 2.0 |
Complement 4/metabolism | 2 | 2.0 |
Complement 6/metabolism | 4 | 40.0 |
Blood Proteins/*metabolism | 2 | 1.0 |
Electrophoresis, Polyacrylamide Gel | 4 | 0.0 |
Immunoglobulins/metabolism | 2 | 1.0 |
Isoelectric Point | 2 | 1.0 |
Complement/*biosynthesis | 5 | 13.0 |
Flow Cytometry | 2 | 0.0 |
Sepharose | 2 | 3.0 |
Acute Disease | 2 | 0.0 |
Complement 7/*immunology | 2 | 100.0 |
Immunoglobulin M/immunology | 2 | 1.0 |
*Complement Pathway, Alternative | 2 | 1.0 |
Japan | 10 | 0.0 |
*Chromosome Deletion | 7 | 0.0 |
Heterozygote Detection | 2 | 0.0 |
Cell Line, Tumor | 2 | 0.0 |
X Chromosome | 3 | 0.0 |
Hemolysis | 11 | 3.0 |
Immunodiffusion | 3 | 1.0 |
Retinitis Pigmentosa/*genetics | 2 | 1.0 |
Fluorescent Antibody Technique | 4 | 0.0 |
Pemphigus/*immunology | 2 | 4.0 |
Complement/biosynthesis/*metabolism | 2 | 66.0 |
Complement Membrane Attack Complex | 15 | 19.0 |
Complement 5/analysis | 3 | 6.0 |
Complement 7/analysis | 5 | 45.0 |
HLA Antigens/*genetics | 3 | 0.0 |
Risk | 2 | 0.0 |
Complement/*deficiency | 2 | 4.0 |
*Blood Bactericidal Activity | 3 | 6.0 |
Complement 3/metabolism | 3 | 1.0 |
Complement 7/metabolism | 3 | 30.0 |
Glycerol Kinase/*deficiency/genetics | 2 | 50.0 |
Phosphotransferases/*deficiency | 3 | 17.0 |
X Chromosome/*ultrastructure | 2 | 8.0 |
Chromosome Banding | 3 | 0.0 |
Trypsin | 2 | 1.0 |
Microscopy, Electron | 2 | 0.0 |
Complement 5/biosynthesis | 2 | 20.0 |
Glomerulonephritis/*immunology | 3 | 7.0 |
Nucleic Acid Hybridization | 2 | 0.0 |
Antibodies | 2 | 0.0 |
Complement 5/immunology | 2 | 11.0 |
Complement 9/immunology | 5 | 29.0 |
Erythrocytes/immunology | 3 | 1.0 |
Complement/*immunology | 4 | 2.0 |
Complement 8/immunology | 3 | 33.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Liposomes | 3 | 1.0 |
Erythrocytes/*immunology | 2 | 1.0 |
Hemoglobinuria, Paroxysmal/*immunology | 2 | 9.0 |
*Hemolysis | 4 | 4.0 |
Immune Sera | 2 | 0.0 |
Basement Membrane/immunology | 2 | 3.0 |
Complement 5/metabolism | 4 | 9.0 |
Phosphatidylcholines | 2 | 5.0 |
Time Factors | 3 | 0.0 |
Complement 6/analysis | 4 | 30.0 |
Complement Pathway, Alternative | 3 | 2.0 |
Blood Bactericidal Activity | 2 | 2.0 |
Gangliosides/*metabolism | 2 | 10.0 |
Cell Membrane/immunology | 2 | 0.0 |
*Complement | 3 | 4.0 |
Chemotaxis | 3 | 1.0 |
*HLA Antigens | 3 | 1.0 |
Opsonins/metabolism | 2 | 8.0 |
Immunoelectrophoresis | 3 | 1.0 |
*Chromosomes, Human, 6-12 and X | 2 | 1.0 |
*Histocompatibility Antigens | 2 | 2.0 |
Lymphocyte Culture Test, Mixed | 2 | 0.0 |
